SRA vs. Holter ECG in the detection of manifest AF, using all recording snips with confirmed AF episodes.

<p>Sensitivity 500/504 = 0.99 specificity 2794/2821 = 0.99.</p><p>SRA, Stroke Risk Analysis system; ECG, electrocardiogram; AF, atrial fibrillation.</p

Overview of the study flow.

<p>AF =  atrial fibrillation; ECG =  electrocardiogram; SRA =  stroke risk analysis.</p

SRA vs. clinical classification (paroxysmal and chronic AF patients combined) using all recording snips (up to 24 hours).

<p>Sensitivity 1164/1930 = 0.60 Specificity 2102/2236 = 0.94.</p><p>SRA, Stroke Risk Analysis system; AF, atrial fibrillation.</p

Clinical characteristics of the study groups.

<p>^* persistent/permanent AF;</p><p>^**Age, body mass index, and heart rate are presented as mean ± standard deviation. AF =  atrial fibrillation; n.a. =  not applicable.</p

SRA vs. clinical classification (paroxysmal only) within the first hour of recording.

<p>Sensitivity 19/47 = 0.40 Specificity 99/100 = 0.99.</p><p>SRA, Stroke Risk Analysis system; AF, atrial fibrillation.</p

SRA vs. clinical classification (paroxysmal and chronic AF patients combined) within the first hour of recording.

<p>Sensitivity 50/85 = 0.59 Specificity 99/100 = 0.99.</p><p>SRA, Stroke Risk Analysis system; AF, atrial fibrillation.</p

Real-world use, safety, and patient experience of 20% subcutaneous immunoglobulin for primary immunodeficiency diseases

   Article full text  The article associated with this page has been accepted for online publication and is in the final stages of production. The link to the full text will be made available on this page in the next few days.  The above graphical abstract represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online. (see “read the peer-reviewed publication” opposite). </p

Prevalence estimates for PAD using different methods for ABI calculation

<p><b>Copyright information:</b></p><p>Taken from "Profound influence of different methods for determination of the ankle brachial index on the prevalence estimate of peripheral arterial disease"</p><p>http://www.biomedcentral.com/1471-2458/7/147</p><p>BMC Public Health 2007;7():147-147.</p><p>Published online 6 Jul 2007</p><p>PMCID:PMC1950873.</p><p></p> PAD was defined by an ABI value < 0.9 or clinical evidence of PAD . Clinical evidence of PAD included positive Rose questionnaire, intermittent claudication and peripheral vascular event

Association between PAD and history of cardiac event using odds ratios (OR)

<p><b>Copyright information:</b></p><p>Taken from "Profound influence of different methods for determination of the ankle brachial index on the prevalence estimate of peripheral arterial disease"</p><p>http://www.biomedcentral.com/1471-2458/7/147</p><p>BMC Public Health 2007;7():147-147.</p><p>Published online 6 Jul 2007</p><p>PMCID:PMC1950873.</p><p></p> PAD was defined by an ABI value < 0.9 or clinical evidence of PAD, while history of cardiac event was evident after myocardial infarction or coronary revascularisation. OR, sensitivity and specificity are shown for the different modes of ABI calculation. Sensitivity and specificity are given for the 'detection' or 'exclusion', resp., of a history of cardiac events

ROC curves for the association between ABI values (according to different methods for ABI calculation) and the history of cardiovascular events (myocardial infarction or coronary revascularisation)

<p><b>Copyright information:</b></p><p>Taken from "Profound influence of different methods for determination of the ankle brachial index on the prevalence estimate of peripheral arterial disease"</p><p>http://www.biomedcentral.com/1471-2458/7/147</p><p>BMC Public Health 2007;7():147-147.</p><p>Published online 6 Jul 2007</p><p>PMCID:PMC1950873.</p><p></p> , method #1; , method #2; , method #3; , method #4. The red dashed line represents the line of identity of tpr and fpr